Increasing resistance to vancomycin; a myth or reality -a review

Journal of Pharmaceutical Sciences and Research

Volumn 3, Issue 12, 2011, Pages 1599-1603

  Farooq, Mehreen ^a   Tarar, Wasam Liaqat ^a   Amin Dr , Fatima ^a   Mahmood, Khwaja Tahir ^b  

^a LAHORE COLLEGE FOR WOMEN UNIVERSITY   (Pakistan)

^b DTL   (Pakistan)

Author keywords

Endocarditis; MRSA; Off label

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CHILL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG UTILIZATION; DYSPHAGIA; DYSPNEA; FEVER; HEALTH CARE POLICY; HUMAN; INAPPROPRIATE PRESCRIBING; INFECTION CONTROL; INFECTION RISK; MEDICATION ERROR; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEPHROTOXICITY; NONHUMAN; OFF LABEL DRUG USE; PHARMACIST ATTITUDE; PRACTICE GUIDELINE; PRURITUS; PSEUDOMEMBRANOUS COLITIS; RASH; SORE THROAT; STAPHYLOCOCCUS INFECTION; TINNITUS; TREATMENT DURATION; URTICARIA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 83655183655     PISSN: None     EISSN: 09751459     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Griffith RS. RevInfect Dis. Introduction to vancomycin. 1981; 3:S200-4.
2. Ena, J., R. W. Dick, R. N. Jones, and R. P. Wenzel, 1993. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA 269:598-602.hylococcus aureus.
3. Wayne, PA: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grows Aerobically-Fourth Edition. Approved Standard NCCLS Document M7-A4, Vol. 17, No.2, NCCLS, January, 1997.
4. Wayne, PA: Performance Standards for Antimicrobial Disk Susceptibility Tests-Sixth Edition. Approved Standard NCCLS Document M2-A6, Vol. 17, No.1, NCCLS, January, 1997.
5. Moellering, R.C., Krogstad, D.J., and Greenblatt, D.J.: Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage, Ann. Intern. Med., 1981; 94:343.
6. The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a604038.html Retrieved on: 18/4/2011
7. Beth A. Logsdon, Kelley R. Lee, Gary Luedtke and Fred F. Barrett Infection Control and Hospital Epidemiology Vol. 18, No. 11 (Nov., 1997), pp. 780-782
8. Kenneth Todar, PhD United States Medical Licensing Examination - Todar's Online Textbook of Bacteriology Textbook Revolution - Todar's Online Textbook of Bacteriology
9. Van Houten MA, Uiterwaal CS, Heesen GJ, Arends JP, Kimpen JL. Wilhelmina Children's Hospital, University Medical Center Utrecht Julius Center for Patient Oriented Research, The Netherlands.
10. Harry L. Keyserling, MD, Ronda L. Sinkowitz-Cochran, MPH, James M. Harris II, MS, Gail L. Levine, MA, Jane D. Siegel, MD, Beth H. Stover, RN, CIC, Sharon A. Lau, AB, MS, William R. Jarvis, MD, the Pediatric Prevention Network
11. R Ramphal, M Bolger, D J Oblon, R J Sherertz, J D Malone, K H Rand, M Gilliom, J W Shands, Jr, and B S Kramer Department of Medicine, University of Florida, Gainesville 32610-0277.
12. Samir S. Shah MD; Matthew Hall, Ph D; Denise M. Goodman, MD, Ms; Pamela Feuer, Archpediatr Adolesc Med.2007; 161:282-290
13. Maria Dell'Aera, Anna Rita Gasbarro, Margherita Padovano, Nicola Laforgia, Donatella Capodiferro, Biagio Solarino, Roberto Quaranta and Alessandro S. Dell'Erba Volume 29, Number 4, 361-367, DOI: 10.1007/s11096-006- 9081-z
14. Elaine L. Larson, RN, PhD, Dave Quirts, MS, Tara Giblin, RN, MPH, and Susan Lin, DrPH, School of Nursing (E.L.L., D.Q., T.G., S.L.) and Mailman School of Public Health (E.L.L.), Columbia University, New York, NY
15. Radford JM. Vancomycin usage review in the era of vancomycin-resistant enterococci (VRE). J Pharm Pract Res 1997; 27: 140.
16. Radford JM. Reducing inappropriate prescribing of vancomycin. J Pharm Pract Res 1998; 28: 400
17. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmidmediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157.
18. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1:57.
19. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin-- United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565.
20. Wood MJ.: Comparative safety of teicoplanin and vancomycin. J Chemother. 2000 Nov; 12 Suppl 5:21-5.
21. Olivier CN, Blake RK, Steed LL, Salgado CD. Infect Control Hosp Epidemiol. 2008 May; 29(5):404-9.
22. George Sakoulas1 and Robert C. Moellering Jr. Division of Infectious Diseases, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachussetts Reprints or correspondence: Dr. George Sakoulas, Div. of Infectious Diseases, New York Medical College, Munger 245, Valhalla, NY 10595
23. CDC. Nosocomial enterococci resistant to vancomycin -- United States, 1989-1993. MMWR 1993; 42:597-9.
24. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16:750-5.
25. Moellering RC Jr. The Garrod lecture: the enterococcus -- a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991; 28:1-12.
26. Mobarakai N, Landman D, Quale JM. In-vitro activity of trospectomycin, a new aminocyclitol antibiotic against multidrug-resistant Enterococcus faecium. J Antimicrob Chemother 1994; 33:319-21.
27. Belinda E. Ostrowsky, M.D., M.P.H., William E. Trick, M.D., Annette H. Sohn, M.D., Stephen B. Quirk, M.P.P., Stacey Holt, M.M.Sc., Loretta A. Carson, M.S., Bertha C. Hill, B.S., Matthew J. Arduino, Ph.D., Matthew J. Kuehnert, M.D., and William R. Jarvis, M.D.N Engl J Med 2001; 344:1427-1433 May 10, 2001
28. Lin MY, Hayden MK. Departments of Medicine, Rush Medical College, Chicago, IL, USA.
29. Taly Drori-Zeides, MD David Raveh, MD, Yechiel Schlesinger, MD, Amos M. Yinnon, MD.: Practical Guidelines for Vancomycin Usage, With Prospective Drug-Utilization Evaluation. Infection Control and Hospital Epidemiology. Vol. 21, No. 1 (January 2000) (pp. 45-47)
30. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006; 42(suppl 1):S35-9
31. Michael J. Rybak1, Ben M. Lomaestro, John C. Rotscahfer, Robert C. Moellering Jr., Willam A. Craig, Marianne Bulleted, Joseph R. Dalovisio and Donald P. Levine: Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health- System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis. (2009) 49 (3): 325-327.
32. C. A. Bond and Cynthia L. Raehl: Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. American Journal of Health-System Pharmacy August 1, 2005 vol. 62 no. 15 1596-1605
33. PP Believes, AL Rothman, and CE Maday: Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium. American Journal of Health- System Pharmacy July 1, 1996 vol. 53 no. 13 1570-1575.
34. S. S. Biradar Kles College of Pharmacy S. T. Bhagavati Kles College of Pharmacy R. D. Hunshyal Kles College of Pharmacy Ahmvswamy Kles College of Pharmacy Citation: S.S. Biradar, S.T. Bhagavati, R.D. Hunshyal &. Ahmvswamy: Off - Label Use Of Drugs: Safety Concerns. The Internet Journal of Pharmacology. 2005 Volume 4 Number 1